Jay Venkatesan - Jun 28, 2024 Form 4/A - Amendment Insider Report for Elicio Therapeutics, Inc. (ELTX)

Role
Director
Signature
/s/ Jay Venkatesan
Stock symbol
ELTX
Transactions as of
Jun 28, 2024
Transactions value $
$249,500
Form type
4/A - Amendment
Date filed
1/2/2025, 04:05 PM
Date Of Original Report
Jul 2, 2024
Previous filing
Dec 29, 2023
Next filing
Nov 25, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELTX Common Warrants Purchase $0 +50K $0.00 50K Jun 28, 2024 Common Stock 50K $5.00 Direct F1, F2, F3
transaction ELTX Pre-Funded Warrants Purchase $250K +50K $4.99 50K Jun 28, 2024 Common Stock 50K $0.01 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Common Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $5.00 per share, subject to adjustments as provided under the terms of the Common Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%.
F2 The Common Warrants expire on July 1, 2029.
F3 On July 2, 2024, the Reporting Person mistakenly filed a Form 4 reporting the acquisition of an additional 150,000 Common Warrants and 150,000 Pre-Funded Warrants. The Reporting Person is not the beneficial owner of such Common Warrants or Pre-Funded Warrants. As of January 2, 2025, the Reporting Person owned only the Common Warrants and Pre-Funded Warrants reported herein.
F4 Each Pre-Funded Warrant will be exercisable by the holder at any time on or after July 1, 2024 at an exercise price equal to $0.01 per share, subject to adjustments as provided under the terms of the Pre-Funded Warrant, subject to a post-exercise beneficial ownership limitation of 4.99%.
F5 The Pre-Funded Warrants do not have an expiration date.